参考文献/References:
[1]Power SE,O’Toole PW,Stanton C,et al.Intestinal microbiota, diet and health[J].Br J Nutr,2014,111(3):387-402.[2]Rescigno M.Intestinal microbiota and its effects on the immune system[J].Cell Microbiol,2014,16(7):1004-1013.[3]De Vadder F,Kovatcheva-Datchary P,Goncalves D,et al.Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits[J].Cell,2014,156(1-2):84-96.[4]Mollica MP,Mattace Raso G,Cavaliere G,et al.Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice[J].Diabetes,2017,66(5):1405-1418.[5]Canfora EE,van der Beek CM,Jocken JWE,et al.Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial[J].Sci Rep,2017,7(1):2360.[6]Bouter K,Bakker GJ,Levin E,et al.Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects[J].Clin Transl Gastroenterol,2018,9(5):155.[7]Xiao J,Wang F,Wong NK,et al.Global liver disease burdens and research trends: Analysis from a Chinese perspective[J].J Hepatol,2019,71(1):212-221.[8]Wang HB,Wang PY,Wang X,et al.Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription[J].Dig Dis Sci,2012,57(12):3126-3135.[9]Deng M,Qu F,Chen L,et al.SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD[J].J Endocrinol,2020,245(3):425-437.[10]范秀琴,路媛媛,樊超男,等.乙酸可通过增强脂肪酸β氧化治疗小鼠肥胖[J].中国食物与营养,2017,23(5):69-72.[11]Li Q,Chen H,Zhang M,et al.Altered short chain fatty acid profiles induced by dietary fiber intervention regulate AMPK levels and intestinal homeostasis[J].Food Funct,2019,10(11):7174-7187.[12]Ran B,Guo CE,Li W,et al.Sea buckthorn (Hippophae rhamnoides L.) fermentation liquid protects against alcoholic liver disease linked to regulation of liver metabolome and the abundance of gut microbiota[J].J Sci Food Agric,2021,101(7):2846-2854.[13]Sun B,Jia Y,Yang S,et al.Sodium butyrate protects against high-fat diet-induced oxidative stress in rat liver by promoting expression of nuclear factor E2-related factor 2[J].Br J Nutr,2019,122(4):400-410.[14]Roychowdhury S,Glueck B,Han Y,et al.A Designer Synbiotic Attenuates Chronic-Binge Ethanol-Induced Gut-Liver Injury in Mice[J].Nutrients,2019,11(1):97.[15]Lima-Cabello E,García-Mediavilla MV,Miquilena-Colina ME,et al.Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C [published correction appears in Clin Sci (Lond). 2024 Jun 19;138(12):757-760. doi: 10.1042/CS-2010-0387_COR.][J].Clin Sci (Lond),2011,120(6):239-250. [16]Endo M,Masaki T,Seike M,et al.TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c)[J].Exp Biol Med (Maywood),2007,232(5):614-621.[17]Harte AL,da Silva NF,Creely SJ,et al.Elevated endotoxin levels in non-alcoholic fatty liver disease[J].J Inflamm (Lond),2010,7:15.[18]Bergheim I,Weber S,Vos M,et al.Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin[J].J Hepatol,2008,48(6):983-992.[19]Compare D,Coccoli P,Rocco A,et al.Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease[J].Nutr Metab Cardiovasc Dis,2012,22(6):471-476.[20]Vespasiani-Gentilucci U,Carotti S,Perrone G,et al.Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD[J].Liver Int,2015,35(2):569-581.[21]韩冰.LPS对NAFLD大鼠肝纤维化进程及TLR-4/NF-κB信号通路的影响[D].延吉:延边大学,2018.[22]郭慧慧,申浩然,张红娟,等.灯盏生脉通过调节肠道微环境抑制非酒精性脂肪肝进程[J].药学学报,2022,57(12):3524-3534.[23]鲁旭,韩涛,田垚,等.肠道菌群和胆汁酸代谢对非酒精性脂肪性肝病发生发展的作用[J].临床肝胆病杂志,2014,30(11):1225-1228.[24]OHNO M.[Functional analysis of nuclear receptor FXR controlling metabolism of cholesterol][J].Yakugaku Zasshi,2008,128(3):343-55.[25]张磊,金智生,杨晓轶,等.红芪多糖对非酒精性脂肪肝病细胞模型FXR-SHP-SREBP-1c信号通路的影响[J].中国临床药理学杂志,2024,40(2):200-204.[26]魏珏,叶丽静,邱德凯,等.胆汁酸核受体FXR在非酒精性脂肪性肝病中的作用[J].胃肠病学,2010,15(1):21-24.[27]Sinal CJ,Tohkin M,Miyata M,et al.Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J].Cell,2000,102(6):731-744.[28]Yang ZH,Liu F,Zhu XR,et al.Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis[J].World J Gastroenterol,2021,27(24):3609-3629.[29]Wang YD,Chen WD,Yu D,et al.The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice[J].Hepatology,2011,54(4):1421-1432.[30]Chen WD,Yu D,Forman BM,et al.Deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically induced liver carcinogenesis[J].Hepatology,2013,57(2):656-666.[31]Irving AT,Mimuro H,Kufer TA,et al.The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling[J].Cell Host Microbe,2014,15(5):623-635.[32]Jin M,Lai Y,Zhao P,et al.Effects of peptidoglycan on the development of steatohepatitis[J].Biochim Biophys Acta Mol Cell Biol Lipids,2020,1865(4):158595.[33]Szabo G,Velayudham A,Romics L Jr,et al.Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4[J].Alcohol Clin Exp Res,2005,29(11 Suppl):140S-145S.[34]Barrea L,Annunziata G,Muscogiuri G,et al.Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome[J].Nutrients,2018,10(12):1971.[35]León-Mimila P,Villamil-Ramírez H,Li XS,et al.Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes[J].Diabetes Metab,2021,47(2):101183.[36]Tan X,Liu Y,Long J,et al.Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease[J].Mol Nutr Food Res,2019,63(17):e1900257.[37]Dumas ME,Barton RH,Toye A,et al.Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice[J].Proc Natl Acad Sci U S A,2006,103(33):12511-12516.[38]廖沛球,魏来,刘威,等.给药硝酸钕后大鼠完整肝组织及肝组织提取物的NMR代谢组学研究[J].高等学校化学学报,2009,30(6):1116-1120.[39]Mir H,Meena AS,Chaudhry KK,et al.Occludin deficiency promotes ethanol-induced disruption of colonic epithelial junctions, gut barrier dysfunction and liver damage in mice[J].Biochim Biophys Acta,2016,1860(4):765-774.[40]Zhu L,Baker SS,Gill C,et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH[J].Hepatology,2013,57(2):601-609.[41]Ritze Y,Bárdos G,Hubert A,et al.Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice[J].Br J Nutr,2014,112(1):1-7.[42]Pisanti S,Picardi P,Ciaglia E,et al.Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation[J].FASEB J,2014,28(3):1132-1144.[43]Zhang X,Coker OO,Chu ES,et al.Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J].Gut,2021,70(4):761-774.[44]Zhao ZH,Xin FZ,Xue Y,et al.Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats[J].Exp Mol Med,2019,51(9):1-14.[45]Wang H,Shi X,Qiu M,et al.Hydrogen Sulfide Plays an Important Role by Influencing NLRP3 inflammasome[J].Int J Biol Sci,2020,16(14):2752-2760.[46]Osawa Y,Kanamori H,Seki E,et al.L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin[J].J Biol Chem,2011,286(40):34800-34808.
相似文献/References:
[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(04):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]冯贺强,张彩红.肠道菌群与非酒精性脂肪肝关系的研究进展[J].医学信息,2018,31(12):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
FENG He-qiang,ZHANG Cai-hong.Research Progress on the Relationship between Intestinal Flora and Nonalcoholic Fatty Liver[J].Journal of Medical Information,2018,31(04):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
[3]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Journal of Medical Information,2018,31(04):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[4]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of
Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(04):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[5]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in
A Certain Area of Tianjin[J].Journal of Medical Information,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[6]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(04):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
[7]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病
中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with
Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(04):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
[8]蒋晓倩,梁惠卿,刘垚昱,等.吴耀南运用“浊毒”理论论治非酒精性脂肪性肝病验案举隅[J].医学信息,2020,33(04):158.[doi:10.3969/j.issn.1006-1959.2020.04.052]
[9]蔡秀媛,吴春城,梁惠卿,等.非酒精性脂肪性肝病中医证型与客观指标的相关性[J].医学信息,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
CAI Xiu-yuan,WU Chun-cheng,LIANG Hui-qing,et al.Correlation Between TCM Syndromes of Nonalcoholic Fatty Liver Disease and Objective Indexes[J].Journal of Medical Information,2020,33(04):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
[10]徐云云,刘尚全.钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并非酒精性脂肪肝病的研究[J].医学信息,2021,34(01):33.[doi:10.3969/j.issn.1006-1959.2021.01.010]
XU Yun-yun,LIU Shang-quan.Study of Sodium-glucose Cotransporter 2 Inhibitor in the Treatment of Type 2 Diabetes with Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2021,34(04):33.[doi:10.3969/j.issn.1006-1959.2021.01.010]